GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine targets cancer left behind after surgery
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized cancer vaccine for people with bladder or gastroesophageal cancer who have tiny amounts of cancer still detectable after surgery. The vaccine is custom-made from each patient's unique tumor markers and aims to train the immune system to…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated May 07, 2026 18:43 UTC
-
New drug cocktails aim to boost stomach cancer surgery success
Disease control Recruiting nowThis study tests new drug combinations given before and after surgery for people with a type of stomach or esophagus cancer that can be removed. The goal is to see if these treatments are safe and help shrink or eliminate the tumor before surgery. About 100 adults who have not ha…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 10:17 UTC
-
Smart chemo: tailoring treatment to tumor response in stomach cancer
Disease control Recruiting nowThis early-phase trial is testing whether adjusting chemotherapy based on how the tumor responds can help more people with stomach or gastroesophageal junction cancer complete their treatment and have surgery. About 20 adults with stage IB to III disease will receive a personaliz…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 26, 2026 10:13 UTC
-
New hope for stomach cancer patients: experimental drug combos enter trial
Disease control Recruiting nowThis study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus standard chemotherapy, o…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 10:11 UTC
-
New hope for stomach cancer: first human trial of BDC-4182 begins
Disease control Recruiting nowThis early-phase study tests a new drug called BDC-4182 in people with advanced stomach or gastroesophageal cancer that has spread or cannot be removed. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors or slow the disease…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:10 UTC
-
New hope for advanced stomach and pancreatic cancers: extra attack when DNA levels hit zero
Disease control Recruiting nowThis study tests whether adding a second round of targeted treatment (called cytoreductive intervention) after standard chemotherapy can help people with advanced upper GI cancers live longer without the disease getting worse. It is for patients whose cancer has spread but whose …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New Triple-Drug attack shows promise against tough stomach cancer
Disease control Recruiting nowThis study tests a combination of three drugs (zanidatamab, pembrolizumab, and chemotherapy) in people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer from growing for …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for stomach cancer: experimental drug cocktail enters human trials
Disease control Recruiting nowThis study tests whether adding new investigational drugs to standard chemotherapy and immunotherapy (pembrolizumab) can safely shrink tumors in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. About 160 adults whose …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New Virus-Plus-Cell therapy takes on stomach and colon cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called DISP-10, which combines a virus and specially engineered immune cells, for people with advanced stomach, esophageal, or colorectal cancers that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 66 …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Dispatch Biotherapeutics • Aim: Disease control
Last updated May 20, 2026 12:08 UTC
-
New drug duo aims to halt aggressive stomach cancer
Disease control Recruiting nowThis study tests whether adding a drug called zanidatamab to the usual chemotherapy (paclitaxel and ramucirumab) can slow the growth of advanced HER2-positive stomach, esophageal, or gastroesophageal junction cancer. About 168 people whose cancer has not responded to prior treatm…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 19, 2026 11:47 UTC